6. Reeve J, Lunt M, Felsenberg D et al.: European Prospective Osteoporosis Study Group. Determinants of the size of incident vertebral deformities in European men and women in the sixth to ninth decades of age: the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2003; 18: 1664–1673

7. Lunt M, O’Neill TW, Felsenberg D et al.: Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). Bone 2003; 33: 505–513

8. Cummings SR, Melton LJ: Epidemio-
logy and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761–1767

9. Pfeilschifter J, Pientka L, Scheidt-Nave Ch: Osteoporose in Deutschland 2003 – eine Bestandsaufnahme. MMW Fortschr Med 2003; 145: 42–43

10. Dachverband Osteologie e.V.. DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. Langfassung. Osteologie 2009; 18: 304–328

11. Pfeilschifter J: German Specialist Organisation for Osteology. 2006 DVO-
guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60 executive summary guidelines. Exp Clin Endocrinol Diabetes 2006; 114:
611–622

12. Roth A, Abendroth K: Osteoporose. Orthopädie Up2date 2006; 3: 223–243.

13. de Laet CE, van der Klift M, Hofman A et al.: Osteoporosis in men and women: a story about bone mineral density thresholds and hip fracture risk. J Bone Miner Res 2002; 17: 2231–2236

14. Genant HK, Delmas PD, Chen P et al.: Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos Int 2007; 18: 69–76

15. Roth A, Abendroth K, Lehmann G: Indikationen und Voraussetzungen zur Knochenbiopsie. Z Orthop Unfall 2012; 150: 495–498

16. Chapuy MC, Arlot ME, Delmas PD et al.: Effect of calcium andcholecalciferol treatment for three years on hip frac-
tures in elderly women. BMJ 1994; 308: 1081–1082

17. Black DM, Cummings SR, Karpf DB et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535–1541

18. Cummings SR, Black DM, Thompson DE et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077–2082

19. Kanis JA, Barton IP, Johnell O: Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 2005;16:
475–482

20. Black DM, Delmas PD, Eastell R et al.: HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809–1822

21. Reginster JY, Kaufman JM, Goemaere S et al.: Maintenance of antifracture efficacy over 10 years with strontium
ranelate in postmenopausal osteoporosis. Osteoporos Int 2012; 23: 1115–1122

22. Kanis JA, Johnell O, Black DM et al.: Effect of raloxifene on the risk of new vertebral fracture in postmenopausal
women with osteopenia or osteoporosis: a reanalysis of the Multiple Out-
comes of Raloxifene Evaluation trial. Bone 2003; 33: 293–300

23. Neer RM, Arnaud CD, Zanchetta JR et al.: Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;
344: 1434–1441

24. Marcus R, Wang O, Satterwhite J e t al.: The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal
women with osteoporosis. J Bone Miner Res 2003; 18: 18–23

25. Orwoll ES, Scheele WH, Paul S et al.: The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9–17

26. Sutton EE, Riche DM. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis. Ann Pharmacother 2012; 46: 1000–1009

27. Steinhaus M, Schöffel D: Leitliniengerechte Schmerztherapie. Ist das WHO-Stufenschema anwendbar? Osteologie 2008; 17: 205–211

28. Lange U, Uhlemann C: Differenzialindikative physikalische Schmerztherapie der Osteoporose. Osteologie 2008; 17: 212–215

29. Kurth A, Rauschmann M: Evidenz für die Osteoplastie der Wirbelsäule bei osteoporotischen Wirbelkörperfrakturen. Osteologie 2012; 21: 163–167

30. Schott C, Steinhaus M, Schöffel D: Schmerzen bei osteoporotischen Frakturen im zeitlichen Verlauf. Osteologie 2008; 17: 200–203

31. Bonnaire F, Lein T, Weber A: Die Problematik der Schenkelhalsfrakturen. Osteologie 2009; 18: 89–95

32. Ruecker AH, Rupprecht M, Hoffmann M et al.: Subtrochantäre Frakturen. Osteologie 2009; 18: 96–101

Fussnoten

Orthopädische Klinik, Waldkrankenhaus Rudolf-Elle, Eisenberg

Klinik Innere Medizin III, Friedrich-Schiller-Universität Jena

DOI 10.3238/oup.2013.0122–0128